Claims

1. Obinutuzumab, for use in the treatment of cancer in combination with a CD22 antibody-drug conjugate anti-CD22-MC-vc-PAB-MMAE, wherein the anti-CD22 antibody in said CD22 antibody-drug conjugate comprises the light chain variable domain SEQ ID NO: 50 and the heavy chain variable domain SEQ ID NO: 51.

2. Obinutuzumab for use according to claim 1, characterized in that said cancer is a CD20 expressing cancer.

3. Obinutuzumab for use according to any one of claims 1 to 2, characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.

4. Obinutuzumab for use according to any one of claims 1 to 3, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are to be administered.

5. A composition for use in the treatment of cancer comprising obinutuzumab and a CD22 antibody-drug conjugate anti-CD22-MC-vc-PAB-MMAE, wherein the anti-CD22 antibody in said CD22 antibody-drug conjugate comprises the light chain variable domain SEQ ID NO: 50 and the heavy chain variable domain SEQ ID NO: 51.

6. The composition for use according to claim 5, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are to be administered.